Proposed pathogenesis for atypical femoral fractures: Lessons from materials research

Bone

Volumn 55, Issue 2, 2013, Pages 495-500

  Ettinger, B ^a   Burr, D B ^b   Ritchie, R O ^c,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Lawrence Berkeley National Laboratory   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Aging; Atypical femoral fractures; Bisphosphonates; Bone biomechanics; Bone quality; Bone turnover

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN FIBRIL; CONJUGATED ESTROGEN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ATYPICAL FEMORAL FRACTURE; BIOMECHANICS; BONE DENSITY; BONE FRAGILITY; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CORTICAL BONE; EDITORIAL; FEMUR FRACTURE; HUMAN; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; STRESS FRACTURE; TRABECULAR BONE;

BONE REMODELING; FEMORAL FRACTURES; HUMANS;

EID: 84878953361     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.02.004     Document Type: Editorial

References (33)

1. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Alder R.A., Brown T.D., et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
2. Koh J.S., Goh S.K., Png M.A., Ng A.C., Howe T.S. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 2011, 52:77-80.
3. Ahlman M.A., Rissing M.S., Gordon L. Evolution of bisphosphonate-related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res 2012, 27:496-498.
4. Mohan P.C., Howe T.S., Koh J.S., Png M.A. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol 2012, 23:222-227.
5. Fuchs R.K., Allen M.R., Ruppel M.E., Dikab T., Phipps R.J., Miller L.M., et al. In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. Matrix Biol 2008, 27:34-41.
6. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., Felsenberg D., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004, 20:433-439.
7. Harrington J.T., Ste-Marie L.-G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74:129-135.
8. Ott S.M. What is the optimal duration of bisphosphonate therapy?. Cleve Clin 2011, 78:619-630.
9. Kimmel D.B., Recker R.R., Gallagher J.C., Vaswani A.S., Aloia J.F. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner 1990, 11:217-235.
10. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
11. Bone H.G., Greenspan S.L., McKeever C., Bell N., Davidson M., Downs R.W., et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000, 85:720-726.
12. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gotschalk F.A., Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
13. Chapurlat R.D., Arlot M., Burt-Pichat, Chavassieux P., Roux J.P., Portero-Muzy N., et al. Microcrack frequency and bone remodeling in postmenopausal women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007, 22:1502-1509.
14. Zimmerman E.A., Schaible E., Bale H., Barth H.D., Tang S.Y., Reichert P., et al. Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales. Proc Natl Acad Sci 2011, 108:14416-14421.
15. Nalla R.K., Kinney J.H., Ritchie R.O. Mechanistic fracture criteria for the failure of human cortical bone. Nat Mater 2003, 2:164-168.
16. Siegmund T., Allen M.R., Burr D.B. Failure of mineralized collagen fibrils: modeling the role of collagen cross-linking. J Biomech 2008, 41:1427-1435.
17. Bala Y., Depalle B., Farlay D., Douillard T., Meille S., Follet H., et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 2012, 27:825-834.
18. Karim L., Vashishth D. Heterogeneous glycation of cancellous bone and its association with bone quality and fragility. PLoS One 2012, 7:e35047.
19. Tang S.Y., Zeenath U., Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007, 40:1144-1151.
20. Vashishth D., Gibson G.J., Khoury J.I., Schaffler M.B., Kimura J., Fyhrie D.P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:195-201.
21. Boskey A.L., Spevak L., Weinstein R.S. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2009, 20:793-800.
22. Donnelly E., Meredith D.S., Nguyen J.T., Gladnick B.P., Rebolledo B.J., Schaffer A.D., et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012, 27:672-678.
23. Tjhia C.K., Odvina C.V., Rao D.S., Stover S.M., Wang X., Fyhrie D.P. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011, 49:1279-1289.
24. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
25. Mori S., Burr D.B. Increased intracortical remodeling following fatigue damage. Bone 1993, 14:103-109.
26. Li J., Mashiba T., Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001, 69:281-286.
27. Stepan J.J., Burr D.B., Pavo I., Siposa A., Michalska D., Li J., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007, 41:378-385.
28. Chapurlat R.D., Arlot M., Burt-Pichat B., Chavassieux P., Roux J.P., Portero-Muzy N., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates. A bone biopsy study. J Bone Miner Res 2007, 22:1502-1509.
29. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
30. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quant S.A., et al. Effects of continuing or stopping alendronate after 5years of treatment: the fracture intervention long-term extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
31. Dell R.M., Adams A., Greene D.F., Funahashi T.T., Silverman S.L., Eisemon E.O., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
32. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
33. Lo J.C., Huang S.Y., Lee G.A., Khandewal S., Provus J., Ettinger B., et al. Clinical correlates of atypical femoral fracture. Bone 2012, 51:181-184.